Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects

摘要

BackgroundDiabetes is the leading cause of end-stage renal disease (ESRD) and accounts for 40-50% of patients requiring renal replacement therapy. The main pathophysiology of diabetic nephropathy comprises glucose-dependent pathways, hemodynamic pathways, and genetic factors.